Piper Sandler Raises REGN Price Target to $865

On October 19, 2026, Piper Sandler maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (REGN) while lifting its price target from $854.00 to $865.00. The research note reflects the firm's outlook on the biotechnology developer as it prepares for its upcoming financial reporting date.

REGN Regeneron Pharmaceuticals, Inc.

$790.74 ▲ +2.25% year to date

1M 3M YTD

Daily close · Oct 16, 2026

Piper Sandler's Call on Regeneron Pharmaceuticals, Inc.

On October 19, 2026, Piper Sandler maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. while raising its price target from $854.00 to $865.00. Other firms have also adjusted their views recently. For instance, Truist Securities maintained a Buy rating and raised its target from $772.00 to $780.00 on October 7, 2026. Morgan Stanley kept an Equal-Weight rating and lifted its target from $758.00 to $779.00 on the same day. RBC Capital maintained a Sector Perform rating and raised its target from $737.00 to $810.00 on October 8, 2026. Later, on October 15, 2026, UBS upgraded the stock to Buy and boosted its target from $660.00 to $978.00. Consensus analyst figures show a general buy recommendation with a mean price target of $863.93 across 27 total opinions.

Other Institutional Activity in Regeneron Pharmaceuticals, Inc.

Institutional investors continue to adjust their holdings in the biotechnology firm. Dodge & Cox Inc. grew its holdings by 412,838 shares, ending with 4,871,137 shares worth about $3.84 billion. Franklin Resources, Inc. grew its holdings by 49,813 shares, ending with 2,771,839 shares worth about $2.18 billion. Nuveen, LLC reduced its holdings by 45,017 shares, ending with 2,019,974 shares worth about $1.59 billion.

Regeneron Pharmaceuticals, Inc. Stock Down 0.7%

Regeneron shares recently traded around $790.74, sitting up about 0.3% from their event close of $788.00 on October 19, 2026. The stock trades about equal to its 50-day moving average of $790.48 and roughly 7.5% above its 200-day moving average of $735.33. Shares sit 8.0% below their 52-week high of $859.34 and 39.7% above their 52-week low of $566.11.

Recent Earnings

The biotechnology company generates $15.53 billion in trailing-twelve-month revenue with earnings of $40.44 per share. Its net profit margin stands at 27.9% with a return on equity of 14.0%. The next earnings report is scheduled for October 30, 2026.

Dividend

Regeneron pays an annual dividend rate of $3.76 per share, yielding 0.47% with a payout ratio of 9.0%.

Insider Buying and Selling at Regeneron Pharmaceuticals, Inc.

Company insiders have transacted shares in recent months. Director Huda Y. Zoghbi sold 800 shares at a price of $800.00 on August 10, 2026, totaling $640,000. Director Kathryn Guarini sold 400 shares at $800.00 on August 10, 2026, totaling $320,000, and later sold 400 shares at $850.00 on September 2, 2026, totaling $340,000. Officer Marion E. McCourt sold 2,346 shares on September 3, 2026, for a total value of $2,002,458.

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. creates and commercializes specialized medicines to address serious medical conditions worldwide, focusing on eye disorders, inflammatory diseases, cancer, and rare ailments. The company operates from Tarrytown, New York, employing over 15,000 people.

Bottom Line

Piper Sandler's updated price target places fresh attention on the biotechnology firm ahead of its upcoming earnings announcement on October 30, 2026. Market participants will monitor upcoming institutional disclosures and quarterly results for further signals.